The week in health tech, explained in plain English.Get the free newsletter →
November 4, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

FDA Reverses Course on Regenxbio Gene Therapy for Hunter Syndrome

By Healthcare Technology News ·

The FDA is reopening the door to Regenxbio's experimental gene therapy Navsunli, a treatment for Hunter syndrome, a deadly and rare childhood brain disorder. According to STAT News, the agency will reconsider the therapy just four months after rejecting it.

Hunter syndrome, also known as mucopolysaccharidosis type II, is a progressive genetic disease that affects very few children and currently has limited treatment options. The speed of the FDA's about-face is unusual. Agency reversals of this kind typically take longer and require substantial new data or a successful appeal from the developer.

For Regenxbio, the decision revives a program that appeared stalled and offers families a renewed path to a potential therapy. More broadly, the move suggests the FDA is willing to apply added flexibility when evaluating treatments for ultra-rare, life-threatening pediatric conditions, where the calculus around risk and unmet need differs sharply from larger markets. How the reconsideration unfolds will be watched closely across the gene therapy field.

Sources

More in Government

Government

Georgia's Medicaid Work Rules Near Expiration as US Scales Up

Georgia's Pathways to Coverage, the only live Medicaid work requirement program, may expire just as federal rules modeled on it expand nationwide.

Why it matters: Georgia's underperforming experiment is now the template for a national Medicaid policy affecting millions of enrollees.

Government

Valadao Backed Medicaid Work Rules His Own Voters May Dodge

Rep. David Valadao voted for the GOP law imposing Medicaid work requirements, then told his heavily Medi-Cal-dependent California district many residents may be exempt.

Why it matters: The One Big Beautiful Bill's $900 billion in Medicaid cuts and new work rules will reshape coverage, and how exemptions are applied will determine who keeps insurance.

Government

CMS Finalizes Tougher Oversight of Organ Procurement Groups

CMS finalized a rule clarifying when it can decertify underperforming organ procurement organizations and letting top performers expand into more service areas.

Why it matters: Tighter accountability for organ procurement groups could reshape donation coverage and reduce the number of viable organs that go unrecovered.